Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:10/22/2007

working with have solid experience in conducting mid and late stage cancer trials that adhere to FDA and international standards. We have been impressed to date by the professionalism of their operations, the efficiency of their patient recruitment infrastructure and their commitment to patient welfare."

Tumor response in this new study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to ICH and GCP guidelines.

According to the World Health Organization, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 U.S. women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase ll trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer is currently undergoing regulatory review in India. A protocol for a Phase ll trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is also under regulatory review in India. Bavituximab is in clinical trials in the U.S. i
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Decision Resources ... Physician™ 2014, finds that online information and ... brands to differentiate their offering and support ... device purchasing decisions rely on websites, mobile ... about devices—and these physicians are looking to ...
(Date:9/15/2014)... MINNEAPOLIS , Sept. 15, 2014 ... a non-profit professional association serving more than 4,500 ... released its 2015 SCALENDAR, which chronicles corporate fines ... compliance and ethics professionals have a ready reference ... "We developed the SCALENDAR to help ...
(Date:9/15/2014)... -- Research and Markets has announced the addition ... Tests, 9th Edition" report to their offering. ... testing market and all of its segments, providing customers with ... For Business Planning. This is the ninth edition ... 2013 and early 2014. New entrants, new technologies have entered ...
Breaking Medicine Technology:Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... 2012 Mylan Inc. (Nasdaq: MYL ) today announced its ... Financial Results Adjusted diluted EPS of ... for the same prior year period, an increase of 18%; ... 31, 2011 compared to $1.61 for the prior year, an increase of ...
... CITY, N.J., Feb. 21, 2012 S1 Pharmaceuticals, Inc. ... New Drug (IND) application to the U.S. Food and ... (Lorexys).  Lorexys is the Company,s lead drug candidate for ... Female Sexual Dysfunction (FSD).  Lorexys, clinical ...
Cached Medicine Technology:Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 16S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) 2
(Date:9/16/2014)... 16, 2014 Triad Semiconductor, Inc. today ... of Intersil and former President of Linear Technology Corporation ... “David has extraordinary technology and business expertise, and we ... directors,” said Lynn Hayden, Triad CEO and chairman. , ... and mixed signal semiconductor experience to Triad's board. From ...
(Date:9/15/2014)... 16, 2014 The team of defective ... Danis & Lowe report that the company behind ... responsible for the injuries that a woman sustained after ... stress urinary incontinence (SUI). , Carey Danis & Lowe ... litigation and personal injury law. The St. Louis law ...
(Date:9/15/2014)... iFitDress.com, one of the most distinguished dress companies, has ... dresses to its online store. In addition, the company ... They are now provided at very low prices, up to ... confidence in the newly unveiled sapphire evening outfits. “I believe ... all over the world. Up to now, over 200 items ...
(Date:9/15/2014)... 2014 Imaging can be a cost-effective ... might benefit from aggressive intervention, according to a new ... , The study looked at people with asymptomatic carotid ... supplying blood to the head due to atherosclerosis, or ... of up to 20 percent of ischemic strokes, which ...
(Date:9/15/2014)... September 15, 2014 Ticket Down ... tickets for her 2015 Honeymoon Tour. Ariana Grande ... of Boca Raton, Florida has been active in the music ... album, which reached the top of the charts in the ... Association of America for selling more than 400,000 copies. Less ...
Breaking Medicine News(10 mins):Health News:David Bell Joins Triad Semiconductor's Board of Directors 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Beautiful Sapphire Evening Dresses Provided By iFitDress.com 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 3
... ... , ... May 6, 2010 -- CosmoCom the global leader in Contact Center Consolidation 2.0, ... 2010 Long Island Software Award (LISA). Presented by the Long Island Software and Technology ...
... ... are many Americans struggling to find steady employment in a highly competitive market. In order ... to provide a more youthful, refreshed appearance. Non-surgical med spa treatments can offer many benefits ... ...
... ... are interested in achieving top performance from GPUs in diverse applications using Monte Carlo ... the Numerical Algorithms Group (NAG). , ... (Vocus) May 6, 2010 -- Developers and researchers who are interested ...
... In ... leading online fresh-from-the-farm food and grocery delivery service, is celebrating Nurse Appreciation Week (May ... to nurses at five community hospitals in Westchester and Greenwich, CT. , ... Long Island City, NY ...
... ... its corporate headquarters to King Farm in Rockville, Maryland. The move comes at a time ... ... comprehensive HR solutions, recently announced plans to move its corporate headquarters to King Farm in ...
... There,s no safe amount of alcohol for women during this ... Pregnant woman may have another reason to avoid drinking, with ... the risk for a rare blood cancer in children. , ... acute myeloid leukemia (AML), an often fatal blood cancer, increased ...
Cached Medicine News:Health News:CosmoCom Wins Software Award for CosmoHealth 2Health News:CosmoCom Wins Software Award for CosmoHealth 3Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 2Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 3Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 2Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 3Health News:FreshDirect Celebrates Nurse Appreciation Week with Delivery of Complimentary 4-Minute Meals for Nurses at Hospitals in Westchester and Greenwich, CT 2Health News:FreshDirect Celebrates Nurse Appreciation Week with Delivery of Complimentary 4-Minute Meals for Nurses at Hospitals in Westchester and Greenwich, CT 3Health News:Astra HR Moves its Corporate Headquarters to King Farm, Rockville, MD 2Health News:Astra HR Moves its Corporate Headquarters to King Farm, Rockville, MD 3Health News:Drinking While Pregnant Tied to Rare Leukemia in Offspring 2Health News:Drinking While Pregnant Tied to Rare Leukemia in Offspring 3
For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
Medicine Products: